Melexis N.V.

Transaction in Own Shares • Dec 10, 2024

Press release Regulated Information - Inside information

Launch of share buy-back program

Ieper, Belgium – 10 December 2024, 07.00 hrs CET

Melexis NV (Euronext Brussels: MELE) ("Melexis") announces the launch of a share buy-back program

Melexis' Board of Directors has decided to initiate a share buy-back program of its outstanding common stock for up to 850 thousand shares for an amount of up to EUR 50 million. This follows the shareholders' authorization granted in November 2023. The share buy-back program is scheduled to run from 11 December 2024 until 10 December 2025.

Pursuant to the shareholders' authorization purchases will be effected at a price which will comply with the legal requirements, but which will in any case not be more than 10% below the lowest closing price of the last thirty trading days prior to the acquisition and not more than 5% above the highest closing price of the last thirty trading days prior to the acquisition.

The program will be executed adhering to best practices and will comply with relevant buy-back rules and regulations. Melexis has given a discretionary mandate to an independent financial intermediary to conduct the purchases on the regulated market Euronext Brussels. The bought back shares will be held as treasury shares.

Melexis will inform the market of the progress of the program in accordance with the applicable regulatory requirements.

Contact Investor Relations Email: investor@melexis.com

About Melexis

Melexis designs, develops, and delivers edge sensor and driver solutions with a heart for people and planet. Its mission is to empower engineers to turn their ideas into applications that support the best imaginable future, one that is safe, comfortable and sustainable.

Melexis specializes in powertrain, thermal management, lighting, e-brake, e-steering and battery solutions for the automotive sector. It also expands its presence in the emerging markets of sustainable world, alternative mobility, robotics, and digital health.

Founded in 1989 in Belgium, Melexis has grown to employ over 2,000 people in 12 countries, delivering cutting-edge technology to customers worldwide.

For more information, visit www.melexis.com or follow Melexis on LinkedIn, and YouTube.

Disclaimer

Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forwardlooking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.